The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Up-front fees paid out by biopharma companies to seal licensing deals noticeably dipped in the second quarter of the year – then Gilead and Galapagos came along.
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.